Show simple item record

dc.contributor.authorMin, Emily A.en_US
dc.contributor.authorAdediran, Timileyanen_US
dc.contributor.authorThom, Kerri A.en_US
dc.contributor.authorHeil, Emily L.en_US
dc.date.accessioned2020-03-06T17:40:53Z
dc.date.available2020-03-06T17:40:53Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10713/12149
dc.description.abstractBackground: Current guidelines for antimicrobial surgical prophylaxis in ventricular assist device (VAD) patients recommend single-agent cefazolin for either single dose or <24 hr continuation. In the clinical setting, prophylaxis choices for VAD patients historically included broader spectrum agents due to high morbidity and mortality associated with VAD infections. At the University of Maryland, antibiotic choice for surgical prophylaxis in VAD patients historically included broad gram-positive and gram-negative (including Pseudomonas) coverage, often vancomycin/piperacillin-tazobactam, for prolonged periods – increasing risk of antimicrobial resistance. In Oct. 2013, UMMC established standardized prophylaxis protocol for VAD patients: vancomycin + ceftriaxone for 72 hrs. Objective: To evaluate rate of surgical site infection (SSI) in VAD patients after implementation of this protocolen_US
dc.language.isoen_USen_US
dc.subjectventricular assist device patientsen_US
dc.subjectCeftriaxoneen_US
dc.subjectHeart-Assist Devicesen_US
dc.subjectSurgical Site Infection--prevention & controlen_US
dc.subjectVancomycinen_US
dc.titleEvaluation of Surgical Site Infections after Change in Surgical Prophylaxis in Ventricular Assist Device Patientsen_US
dc.typePoster/Presentationen_US
dc.identifier.ispublishedNoen_US
refterms.dateFOA2020-03-06T17:40:54Z


Files in this item

Thumbnail
Name:
SOM_Min_2020.pdf
Size:
97.92Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record